Table 2.
SPM | Target | Bioaction | Reference |
---|---|---|---|
RvD1 | Polymorphonuclear leukocyte | Decreases infiltration in murine skin air pouch model; limits infiltration in renal ischaemic injury | [36,42,43] |
Microglial cells | Inhibits IL-1β expression in vitro | [36] | |
Vascular inflammation (arterial angioplasty) | Attenuates cell proliferation, leukocyte recruitment, and neointimal hyperplasia | [44] | |
Alzheimer’s disease | Stimulates phagocytosis of Aβ by Alzheimer’s disease macrophages | [45] | |
Pain | Controls inflammatory pain | [46] | |
AT-RvD1 | Pain | Controls inflammatory pain | [47] |
Temporomandibular joint inflammation | Limits PMN infiltration to CFA-inflamed TMJ | [48] | |
Arthritis | Antihyperalgesic | [49] | |
Fibromyalgia | Reduces mechanical allodynia and thermal sensitization and prevents depressive behaviour | [50] | |
Postsurgical cognitive decline | Improves postoperative decline and attenuates memory | [51] | |
PD1 | Polymorphonuclear leukocyte | Upregulates CCR5 expression; reduces tissue infiltration | [52,53] |
Macrophages | Stimulates phagocytosis of apoptotic polymorphonuclear leukocyte | [54] | |
T Cell | Promotes apoptosis in vitro | [55] | |
Glial cells | Reduces cytokine production | [56] | |
Epithelial cells | Protects from oxidative stress-induced apoptosis (retinal pigment epithelium) | [38] | |
Eosinophils | Decreases recruitment in response to allergen | [57] | |
RvD2 | Macroglia | Prohibits or reduces the activation of macroglia and microglia, respectively | [58] |
- | Downregulates TNF-α, IL-1β, iNOS, NF-k, NO, and ROS production | [35] | |
Burn wound | Prevents secondary thrombosis and necrosis | [48] | |
RvD3 and AT-RvD3 | Neutrophils | Regulates neutrophils and mediators, reducing murine peritonitis and dermal inflammation | [59] |
RvD4 | Protection and resolution of inflammation during bacterial infection | Stops leukocyte influx to the site of infection in the dorsal pouch cavity as well as the inflammation-initiating eicosanoids by reducing levels of PGD2 and LTB4 | [60] |
RvD5 | Bacterial infection | Increases survival and lower antibiotic requirement | [48] |
RvD6 | Corneal nerve | Decreases inflammation and increases wound healing and nerve regeneration by decreasing the expression of the ACE2 receptor, furin, and integrins. | [61] |
MaR1 | Pain | Controls inflammatory pain | [37] |
Tissue regeneration | Promotes tissue regeneration in planaria | [37] | |
Neuroprotection | Treats amyotrophic lateral sclerosis and spinal muscular atrophy Accelerates clearance of neutrophils and a reduction in macrophage accumulation at the lesion site |
[62,63] | |
MaR2 | Macrophage phagocytosis | Anti-inflammatory activity | [64] |